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ABSTRACT 3-methyladenine (3MeA) DNA glycosylases
remove 3MeAs from alkylated DNA to initiate the base
excision repair pathway. Here we report the generation of mice
deficient in the 3MeA DNA glycosylase encoded by the Aag
(Mpg) gene. Alkyladenine DNA glycosylase turns out to be the
major DNA glycosylase not only for the cytotoxic 3MeA DNA
lesion, but also for the mutagenic 1,N6-ethenoadenine («A)
and hypoxanthine lesions. Aag appears to be the only 3MeA
and hypoxanthine DNA glycosylase in liver, testes, kidney, and
lung, and the only «A DNA glycosylase in liver, testes, and
kidney; another «A DNA glycosylase may be expressed in lung.
Although alkyladenine DNA glycosylase has the capacity to
remove 8-oxoguanine DNA lesions, it does not appear to be the
major glycosylase for 8-oxoguanine repair. Fibroblasts de-
rived from Aag 2y2 mice are alkylation sensitive, indicating
that Aag 2y2 mice may be similarly sensitive.
In the face of inescapable DNA-damaging agents and inevi-
table spontaneous DNA degradation, the constant challenge
to preserve genomic integrity has been met by the evolution of
numerous pathways that protect against the genotoxic effects
of DNA-damaging agents. Unless processed properly, DNA
damage can be mutagenic, carcinogenic, and teratogenic, and
DNA damage also may contribute to aging (1).
Alkylating agents are found in our environment, in our food,
inside all cells as natural metabolites, and in the clinic as cancer
chemotherapeutic agents. Base excision repair (BER) is one of
the major pathways for the repair of damaged DNA bases and
proceeds through a sequence of reactions requiring several
different enzymes. The first step involves excision of the
damaged base (for which most cells are known to have several
different DNA glycosylases). Base excision by glycosylases is
followed by strand cleavage in the vicinity of the abasic site (by
AP endonuclease or AP lyase), and preparation of the DNA
ends for gap filling and ligation. DNA polymerase fills the gap,
and DNA ligase seals the remaining nick, thus completing the
BER process (1).
Human and rat 3-methyladenine (3MeA) DNA glycosylases,
so named because 3MeA was the first substrate identified for
this class of enzymes (2), actually display an unexpectedly
broad substrate range, including guanines methylated at the
N3 or the N7 position (3–6), deaminated adenine [i.e., hypo-
xanthine (Hx)] (7), oxidized guanine 8-oxoguanine (8oxoG)
(8), cyclic etheno adducts on both adenine and guanine (9, 10),
and haloethylated purines (unpublished observations). The
mouse alkyladenine DNA glycosylase (Aag) has not been
assayed for release of all of these substrates, though it has been
shown to act on N3 and N7 methylpurines and on 8oxoG (8,
11). The precise biological effects of all of the DNA lesions
repaired by mammalian 3MeA DNA glycosylases are not yet
known for mammals, though there is strong evidence that
3MeA is cytotoxic (12), and other lesions may be mutagenic,
namely Hx (13), 8oxoG (14), 1,N6-ethenoadenine («A), and
N2,3-ethenoguanine (15, 16). It is important to note that each
of these DNA lesions can arise spontaneously in the DNA of
untreated mammalian cells (17–21), that Hx and 8oxoG are
induced by cigarette smoke (22, 23), and that ethenopurines
are induced by the carcinogenic industrial chemical vinyl
chloride (24). These findings raise the possibility that the
mammalian 3MeA DNA glycosylase may influence spontane-
ous mutation as well as protect against environmental geno-
toxic agents. Here we describe the generation of Aag null
animals, a BER-deficient animal model. Surprisingly, the Aag
gene product seems to be the only measurable DNA glycosy-
lase, in several mouse tissues, that is active against 3MeA, Hx,
and «A.
MATERIALS AND METHODS
Reagents. Enzymes were purchased from New England
Biolabs and Boehringer Mannheim. DNA probes were syn-
thesized with NEBlot (New England Biolabs) and labeled with
[32P]a-dCTP (NENyDuPont). E14 embryonic stem (ES) cells
were provided by A. Berns and H. te Riele, Netherlands
Cancer Institute, Amsterdam.
Partial Purification of Mouse Aag. The Aag cDNA was
subcloned into pRSETA to express polyhistidine-tagged Aag
(His-Aag) and purified according to manufacturer’s instruc-
tions (Invitrogen). The identical purification procedure was
performed on control JM109 cells lacking any expression
vector to create negative control extracts. Purification of
His-Aag away from the endogenous 3MeA DNA glycosylase
activity of JM109 was confirmed by showing that control
JM109 extracts have no residual 3MeA DNA glycosylase
activity (data not shown).
Creation of Aag Heterozygous ES Cells by Targeted Homol-
ogous Recombination. E14 ES cells were cultured on 0.1%
gelatin-coated dishes in DMEMy60% Buffalo rat liver-
conditioned medium (25), supplemented with 10% fetal calf
serumy1% nonessential amino acids (GIBCOyBRL)y0.1 mM
2-mercaptoethanoly50 units/ml of penicilliny50 mg/ml of strep-
tomyciny1,000 units/ml of leukemia inhibitory factor
(GIBCOyBRL). Ten to 15 micrograms of Aag-targeting con-
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struct was prepared as described (12) and electroporated into
107 129yOla-derived E14 ES cells in PBS at 385 Vycm, 1,200
mF, for 10 msec by using a Progenitor II PG200, Hoefer
Gene-pulser. G418 (200 mgyml) and 1-(29-deoxy,29-f luoro-b-
D-arabinofuranosyl)-5 iodouracil (0.2 mM; Bristol Myers
Squibb) resistant clones were expanded into duplicate 24-well
dishes without feeders. Half of the cultures were frozen at
280°C in ES mediumy10% dimethyl sulfoxide, and genomic
DNA was isolated from the other half as described (26).
Homologous recombinants were identified by Southern anal-
ysis (12) and reconfirmed by probing with neo and herpes
simplex virus-tk specific probes (data not shown).
Genotyping Mouse Cells and Tissues. Ear punches were
prepared for PCR as described (27). DNA was isolated from
spleen by using a QIAmp Tissue Kit (Qiagen). Southern
analysis was performed as described (12). Three primers were
used in multiplex PCR analysis of DNA. PI (59GCAGCGACT-
GGCAGATTC) and PIII (59GAAATGCACGGGC-
TAGGG) detect the wild-type allele (164 bp), and primers PII
(which hybridizes the neo cassette; 59AGAAGGGTGAGAA-
CAGAG) and PIII detect the targeted allele (523 bp). The
faint band above the 523-bp product appearing in Fig. 1B
disappeared under optimal reaction conditions. The 2,160-bp
PIyPIII product is not observed under these PCR conditions.
Cycling was done at: 95°C 5 miny55°C 2 miny72°C 1 min (1
cycle); 95°C 1 miny55°C 1 miny72°C 1 min (30 cycles); 95°C 1
miny55°C 4 miny72°C 10 min (1 cycle).
Generation of Aag 1y1, 1y2, and 2y2 Mice. Ten to
fifteen karyotypically normal ES clones were injected into
C57BLy6 blastocysts and transferred into pseudopregnant
female BCBA mice. Male chimeras were crossed with
C57BLy6 females, and germ-line transmission was determined
by the transmission of the agouti coat color.
Preparation of Protein Extracts. Aag 1y1 and Aag 2y2 ES
cell protein extracts were prepared as described (12). Mouse
tissues were thawed on ice in 2.5 vol of glycosylase buffer (20
mM TriszHCl, pH 7.8y100 mM KCly2 mM EDTAy5 mM
2-mercaptoethanol) supplemented with 1.5% triton and pro-
tease inhibitors (100 mM benzamidine HCl, 1 mgyml leupep-
tin, pepstatin A, and aprotinin; Sigma). Tissues were dounce
homogenized, sonicated, and centrifuged (20 min, 14,000 g,
4°C). Protein concentrations of the supernatants were deter-
mined by Bradford analysis (Bio-Rad).
3MeA DNA Glycosylase Activity Assay. 3MeA DNA glyco-
sylase activity was measured as described (6). Briefly, extract
protein was incubated for 5 hr at 37°C with 27.6 mg of 17.9
Ciymmol N-[3H]methyl-N-nitrosourea (Amersham)-treated
calf thymus DNA substrate (2,492 cpmymg, prepared as de-
scribed) (28). Released bases were analyzed by descending
paper chromatography as described (29).
Toxicity Assay of Aag 1y1 and Aag 2y2 Primary Mouse
Embryo Fibroblasts (MEFs). Primary MEFs were isolated
from 13.5-day-old mouse embryos and maintained as de-
scribed (30). 104 cells per 96-well were plated 24 hr before
treatment. Cells were incubated in serum-free media contain-
ing MeOSO2(CH2)2-lexitropsin (Me-Lex) for 1 hr, or exposed
to UV in 0.1 ml PBS. After 72-hr incubation in 0.2 ml of media,
media was brought to 0.5 mgyml 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide, and cells were incubated an
additional 4 hr. Media was replaced with 0.2 ml of dimethyl
sulfoxide, and metabolically active cells were quantified by
absorbance at 560 nm. Four independent samples were aver-
aged, and their standard deviations are indicated. Each curve
was repeated at least three times; representative curves are
shown.
Preparation of Oligonucleotide Substrates for «A, Hx, and
Uracil Glycosylase Activity. The sequence of the «A contain-
ing oligonucleotide has been reported (31) and was a gift from
O. Scharer and G. Verdine, Harvard University, Boston. An
oligo of identical sequence to that of «A was purchased from
Midland Certified Reagents (Midland, TX) with 8oxoG in
place of «A at position 13. The sequence of the uracil
containing oligonucleotide has been reported (32) and was a
gift of B. Demple and R. Bennett, Harvard School of Public
Health, Boston. The Hx-containing oligonucleotide has the
sequence 59-GGATCATCGTTTTT(Hx)GCTACATCGC
(Amitof, Boston). Oligonucleotides were labeled with [32P]g-
ATP (6,000 Ciymmol; NENyDuPont) and 10 units of T4
polynucleotide kinase, and annealed to 2-fold excess comple-
mentary strand. Complete annealing was confirmed by 20%
nondenaturing PAGE (data not shown).
DNA Glycosylase Assays By Using Oligonucleotide Sub-
strates. Protein or protein extracts were incubated with 100
fmols of double-stranded oligonucleotides at 37°C in 20 mM
TriszHCl, pH 7.2y100 mM KCly5 mM EDTAy1 mM EGTAy5
mM 2-mercaptoethanol in a total volume of 30 mL. DNA was
chemically cleaved at abasic sites (0.1 N NaOH, 90°C, 4 min).
Reactions were analyzed by 20% denaturing PAGE, and
radioactivity was detected by a Bio-Rad PhosphorImaging
system (GS525 Molecular Imager).
RESULTS
Generation of Aag Null Mice. We cloned a murine 3MeA
DNA glycosylase gene (Aag) to generate Aag-deficient cells
(12) and mice by targeted homologous recombination (Fig.
1A). The targeting strategy used to generate 3MeA DNA
glycosylase-deficient mice has been described (12). Briefly,
Aag exon II was disrupted with a neo expression cassette to
inactivate Aag and to allow selection for integration, and the
FIG. 1. Genotyping Aag 1y1, 1y2, and 2y2 mice. (A) Schematic
representation of a portion of the wild-type and targeted Aag alleles
indicating the location of three primers and HindIII (H) sites. Note
that Aag exon II is disrupted by insertion of a neo expression cassette
to create an Aag null allele. Primers PI and PIII yield a 164-bp
fragment in the presence of the wild-type allele. In the presence of the
targeted allele, primers PII and PIII yield a 523-bp fragment. HindIII
sites are loosely indicated to show that disruption of Aag by neo
insertion increases the size of the HindIII fragment (details have been
presented elsewhere) (12). (B) (Upper) PCR genotyping of MEFs
(lanes 1–5). PCR genotyping of DNA from spleens of mice used in
subsequent biochemical analysis (lanes 6–7). (Lower) Southern blot
analysis of the DNA used for PCR analysis above. HindIII-digested
DNA was probed with a fragment of the Aag gene that lies outside of
the targeting construct (12). The Aag null allele (8.4 kb) and the
wild-type Aag allele (6.3 kb) are indicated.
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herpes simplex virus-tk expression cassette (not shown) was
placed adjacent to the Aag gene fragment to allow selection
against random integration. E14 mouse ES cell transfectants,
enriched for targeted homologous recombinants, were
screened by Southern blot analysis to identify Aag 1y2
heterozygotes (an example of this kind of analysis is shown in
Fig. 1B).
Aag 1y2 ES cells were injected into mouse blastocysts, and
germ-line transmission was obtained from two independent ES
cell clones. Aag 1y2 offspring of chimeric mice were inter-
crossed to generate Aag 2y2 animals, which were identified
by PCR and Southern analysis (an example is shown in Fig. 1B,
lane 7). Approximately 19% of the progeny of Aag 1y2 mice
were homozygous Aag mutants (n 5 139), which is not
significantly different from Mendelian segregation. Thus Aag
does not appear to be required for normal embryonic devel-
opment. To date, Aag homozygous mice are phenotypically
normal with no gross locomotory deficiencies that would hint
of neurological or muscular defects (up to 8 months). In
addition, both male and female homozygous Aag mice are
fertile.
Aag Represents the Major 3MeA DNA Glycosylase in Sev-
eral Mouse Tissues. Escherichia coli and Saccharomyces cer-
evisiae both have at least two different 3MeA DNA glycosy-
lases (19, 33), and although only one class of 3MeA DNA
glycosylases has been cloned to date, mammals also may
express more than one 3MeA DNA glycosylase activity. Al-
though there is no detectable 3MeA DNA glycosylase activity
in pluripotent Aag 2y2 mouse ES cells (12), other activities
could potentially be revealed after differentiation. Indeed,
exposure to endogenous and exogenous DNA-damaging
agents may vary among tissue types, making it useful to
selectively express a different selection of DNA glycosylases in
different cell types. We therefore measured 3MeA DNA
glycosylase activity in liver, testes, kidney, and lung extracts
prepared from Aag 1y1 and Aag 2y2 mice (Fig. 2A). Because
mouse to mouse variation may affect our results, we assayed at
least two independent mice of each genotype. All four wild-
type tissues express robust 3MeA DNA glycosylase activity,
whereas all four Aag 2y2 tissues are devoid of such activity.
It is possible that we were unable to detect a minor 3MeA DNA
glycosylase activity under these conditions. Nevertheless, these
results suggest that these tissues do not constitutively express
a 3MeA DNA glycosylase other than Aag.
We confirmed that the absence of 3MeA DNA glycosylase
activity in Aag 2y2 tissue extracts was not because of a general
enzyme inactivation of these extracts, by showing that Aag
1y1 and Aag 2y2 liver extracts have equivalent uracil DNA
glycosylase activity (Fig. 2B). Further, because 3MeA DNA
glycosylase activity levels have been shown to vary between
mouse strains (34), and because Aag 2y2 mice have a mixed
129 and C57BLy6 genetic background (see Materials and
Methods), we measured 3MeA DNA glycosylase activity in 129
and C57BLy6 mice. These mice displayed robust 3MeA DNA
glycosylase activity in lung, liver, and testes (data not shown;
kidney not tested). Thus, the varied contribution from the 129
and C57BLy6 genetic backgrounds can not account for the
complete lack of activity observed in the Aag 2y2 mice. Taken
together these data indicate: (i) Aag activity was successfully
eliminated in the Aag homozygous null mice; and (ii) Aag is the
major 3MeA DNA glycosylase activity in at least four tissues.
Aag 1y1 and Aag 2y2 testes extracts show essentially
identical 8oxoG DNA glycosylase activity (Fig. 2C). Although
Aag removes 8oxoG in vitro (8), Aag is not a major contributor
toward 8oxoG glycosylase activity, at least in testes. Clearly,
(an)other enzyme(s) contribute the majority of the 8oxoG
DNA glycosylase activity in testes, which is consistent with the
cloning of a novel 8oxoG DNA glycosylase from mammalian
cells (35–39, 59).
Cells Derived from Aag Null Mice Are Sensitive to Alkylat-
ing Agent. Primary MEFs were derived from five 13.5-day
embryos from a cross between two Aag 1y2 mice. PCR and
Southern blot genotyping of these cells are shown in Fig. 1B
(lanes 1–5). MEFs from two Aag 2y2 and two Aag 1y1
embryos were treated with the alkylating agent Me-Lex that
specifically induces 3MeA DNA lesions (40, 41), or with UV.
Aag 2y2 cells are more sensitive to the toxic effects of 3MeA
lesions than Aag 1y1 cells (Fig. 3A), as measured by using an
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assay (see Materials and Methods). However, as expected, Aag
1y1 and Aag 2y2 cells are equally sensitivity to UV (Fig. 3B),
an agent that induces potentially lethal base damages that are
not thought to be substrates of Aag.
FIG. 2. 3MeA, uracil, and 8-oxoG DNA glycosylase activity in
mouse tissue extracts. (A) 1,000 mg (BSA, B; liver, Li; and kidney, K),
500 mg (lung, Lu) or 250 mg (testes, T) of protein extracts from Aag
1y1 or Aag 2y2 tissues were incubated in triplicate reactions for 5
hr at 37°C with [3H]methyl-N-nitrosourea-treated calf thymus DNA.
3MeA was separated from other bases by descending paper chroma-
tography. The cpm associated with 3MeA per mg protein extracts are
indicated for the average of two or three independent mice. Error bars
represent standard deviations. (B) Time-dependent release of site-
specific uracil from 59 32P-labeled double-stranded oligonucleotides by
Aag 2y2 and Aag 1y1 liver extracts. BSA (100 mg) was incubated
with the oligo substrate (first lane). Remaining lanes each contain 100
mg of either Aag 2y2 or Aag 1y1 liver extract. After incubation at
37°C for the times indicated in min beneath each lane, oligonucleotides
were chemically cleaved at abasic sites and analyzed by denaturing
PAGE. DNA glycosylase activity is indicated by the appearance of a
21-mer. (C) Time-dependent release of site-specific 8oxoG from 59
32P-labeled double-stranded oligonucleotides by Aag 2y2 and Aag
1y1 testes extracts. BSA (75 mg) were incubated with the 8oxoG
containing oligonucleotides (first lane). Remaining lanes each contain
75 mg of either Aag 2y2 or Aag 1y1 testes extracts. Samples were
analyzed as described in B. DNA glycosylase activity is indicated by the
appearance of a 12-mer.
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Mouse Aag Releases «A and Hx and Is the Major «A and Hx
DNA Glycosylase in Several Tissues. It previously was estab-
lished that, in addition to 3MeA, the human and rat 3MeA
DNA glycosylases can release «A and Hx from DNA (7, 10,
42), two lesions that promote base mispairing (13, 16). Here we
establish that mouse Aag also repairs «A and Hx. Double-
stranded 25-mer DNA oligonucleotides, containing a single
«A, or a single Hx, located at a defined position, were used as
substrates for the Aag enzyme that was partially purified from
E. coli expressing the Aag cDNA (see Materials and Methods).
Similarly prepared fractions from bacteria lacking the Aag
cDNA were used as a negative control. Abasic sites were
converted to strand breaks to produce either a labeled 14-mer
(for the Hx substrate), or a labeled 12-mer (for the «A
substrate). Fig. 4A clearly shows that Aag can remove Hx and
«A lesions from DNA.
By using Aag 1y1 liver extracts, assay conditions were
optimized for «A and Hx DNA glycosylase activity while
suppressing nonspecific DNA degradation (Fig. 4B). Whereas
Aag 1y1 liver extracts display robust «A and Hx DNA
glycosylase activity that increases with increasing incubation
time, Aag 2y2 liver extracts are completely devoid of these
activities. The same liver extracts show apparently equal uracil
DNA glycosylase activity (Fig. 2B). Similar results were ob-
served for liver extracts from two other mice (Aag 2y2 and
Aag 1y1; data not shown). We infer that Aag is the major «A
and Hx DNA glycosylase in mouse liver. It should be noted that
the «A lesion has been shown to degrade at a slow rate during
storage to form 4-amino-5-(imidazol-2-yl)imidazole (b), which
is even more mutagenic and toxic than «A itself (at least in E.
coli) (43). Such degradation also is likely to occur in vivo. It is
possible that in the results shown here, a small fraction of the
observed cleavage may be because of Aag mediated excision of
the highly mutagenic b adduct; this possibility is currently
under investigation.
Although Aag appears to be the major «A and Hx DNA
glycosylase in mouse liver, it was possible that other activities
could be revealed in other differentiated tissues. Testes, kid-
ney, and lung tissues from two Aag 1y1 and two Aag 2y2
mice were examined for activity on each substrate. Fig. 4 C–E
shows that all three Aag 1y1 tissues display both Hx and «A
DNA glycosylase activity. However, Aag 2y2 testes, kidney,
and lung do not express measurable levels of Hx DNA
glycosylase activity, once again implicating Aag as the major
DNA glycosylase for repair of the mutagenic Hx lesion. In
contrast, the «A DNA glycosylase assays displayed a more
complex picture. Whereas Aag 2y2 testes and kidney do not
express measurable «A DNA glycosylase, there was some
detectable «A DNA glycosylase activity in Aag 2y2 lung (Fig.
4 C–E). However, because Aag represents all of the measurable
«A DNA glycosylase activity in liver, kidney, and testes, and
more than 50% of that in lung (as judged by densitometry, data
not shown), we conclude that Aag represents the major «A
DNA glycosylase activity in all four tissues.
DISCUSSION
The Aag null mice described here are viable animals specifi-
cally mutant in a BER enzyme, albeit in just one of at least six
mammalian DNA glycosylases that can initiate BER. Attempts
to generate mice that are wholly deficient in BER (by inacti-
vating enzymes acting downstream of DNA glycosylases)
revealed that the major mammalian AP-endonuclease gene
(APEyAPEXyREF-1yHAP1) and a major DNA repair poly-
merase gene (b-pol) are essential for normal mouse develop-
ment (44, 45). Because all six or more DNA glycosylases
presumably continue to remove aberrant bases in these ani-
mals, one interpretation of these findings is that the accumu-
lation of abasic sites (in the case of APE homozygous mutants)
or nucleotide gaps (in the case of b-pol homozygous mutants)
is toxic (of course there are other possible explanations for this
embryonic lethality). Our objective is to investigate the bio-
logical consequences of DNA base lesions in the genome, and
this goal may be accomplished by disrupting the enzymes that
initiate BER. We therefore generated Aag homozygous mu-
tant mice.
Here we show that, like its human and rat homologues, the
mouse Aag 3MeA DNA glycosylase is proficient in releasing
«A and Hx in addition to 3MeA. Furthermore, biochemical
characterization of the Aag null mice identify Aag as a major
DNA glycosylase for repair of 3MeA, Hx, and «A DNA lesions
in several major tissues. Aag is not, however, the major DNA
glycosylase for removal of all of the substrates identified in
biochemical assays in vitro, because the Aag 2y2 testes
extracts maintain wild-type levels of 8oxoG DNA glycosylase
activity. Because Aag homozygous mutant mice are viable, we
infer that: (i) the spontaneous DNA lesions repaired by Aag
are not lethal when left unrepaired; or (ii) other DNA repair
enzyme(s) can take over the repair of potentially lethal lesions
normally repaired by Aag. As a first step toward revealing the
biological consequences of an Aag deficiency in mammals, we
have shown that primary fibroblasts derived from Aag 2y2
embryos are more sensitive to the toxic effects of 3MeA lesions
than their wild-type counterparts. We therefore anticipate that
the phenotype of Aag 2y2 animals likewise will include
sensitivity to DNA alkylating agents.
The importance of removing damaged DNA bases from the
genome of mammals has been amply demonstrated by the
observation that mice and people specifically deficient in
nucleotide excision repair have increased susceptibility to
UV-induced tumorigenesis (46–50). The precise biological
effects of the lesions repaired by Aag in animals are not yet
known. However, we recently demonstrated that 3MeA DNA
lesions specifically induce sister chromatid exchanges and
chromosome aberrations (unpublished data), and strong evi-
dence implicates «A and Hx as miscoding lesions (13, 16). It
therefore seems likely that Aag may not only protect animals
against toxicity, but also may limit mutation and, thus, the
appearance of cancers.
3MeA, «A, and Hx are endogenously produced DNA le-
sions. The cellular metabolite S-adenosyl-L-methionine, used
for methyl transfer to numerous cellular constituents, inad-
vertently may alkylate DNA (17, 18). Lipid peroxidation
products, like 2,3-epoxy-4-hydroxynonanal, react with DNA to
form «A (51, 52), and the formation of Hx occurs by sponta-
neous deamination of adenine and by exposure to NOz (pro-
duced by activated macrophages) (19, 53). 3MeA, «A, and Hx
FIG. 3. Toxicity assay of Aag 1y1 or Aag 2y2 MEFs treated with
increasing doses of Me-Lex (A) or UV (B). Percent metabolically
active treated cells is expressed relative to untreated control cells. Cells
from two Aag 2y2 embryos (closed symbols) and two Aag 1y1
embryos (open symbols) were analyzed.
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also are induced by exposure to certain carcinogens in our
environment (23, 24, 54, 55). The Aag 2y2 animals are not yet
old enough to determine if Aag has an influence on sponta-
neous cancer rates, and moreover, the Aag null allele must be
backcrossed at least 10 generations to produce the appropri-
ately inbred genetic background for an accurate comparison of
the relative sensitivities of Aag 2y2, Aag 1y2 and Aag 1y1
mice to genotoxic and carcinogenic agents. However, the
striking biochemical phenotype of the Aag 2y2 genotype
reported here suggests that Aag is likely to be an important
contributor to genomic stability.
The mammalian 3MeA DNA glycosylases release a wide
variety of damaged DNA bases in vitro, but the in vivo repair
of these lesions may or may not be Aag-dependent. Because
the in vitro assays used in this study are specific for the activity
of DNA glycosylases, studies of the in vivo rate of removal of
damaged bases will establish if the Aag substrates can be acted
on by other repair systems. Although nucleotide excision
repair (NER) removes a broad spectrum of DNA lesions and
mismatch repair (MMR) can act on at least one methylated
base (O6 MeG), various studies indicate that neither NER nor
MMR play a predominant role in 3MeA repair (56–58).
However, whether or not the mammalian NER and MMR
pathways can repair Hx and «A lesions has not yet been
addressed, and the possibility that these pathways play a major
role in their repair cannot be eliminated. Monitoring the in
vivo rate of removal of all three lesions in Aag null mice, and
in these mice carrying additional defects in NER or MMR, will
help to reveal the relative importance of the three repair
systems. The appropriate crosses of Aag 2y2, XPA 2y2, and
Msh2 2y2 mice currently are underway.
In summary, the viable and fertile Aag null mice described
here will allow us to explore the role of this repair enzyme in
protecting animals against endogenously produced damaged
DNA bases and base adducts created by cancer chemothera-
peutics or by toxic agents in our food and in our environment.
Given the broad range of substrates repaired by mammalian
3MeA DNA glycosylases, the biological role of Aag may be
multifaceted and may vary among cell types. Further, by
crossing Aag null mice with other genetically engineered
mouse strains, we will be able to study the interplay between
Aag initiated BER and other DNA damage response pathways,
such as those involved in triggering cell cycle arrest and
apoptosis.
FIG. 4. Aag is the major Hx and «A DNA glycosylase in mouse
liver, testes, kidney, and lung. (A) Release of «A and Hx by partially
purified poly-histidine-Aag fusion protein (see Materials and Methods).
59 32P-labeled double-stranded oligonucleotides containing site-
specific «A or Hx were incubated with either polyhistidine-tagged Aag
(lanes 2 and 4) or with negative control extracts from E. coli not
expressing the Aag cDNA protein (see Materials and Methods) (lanes
1 and 3). After 1 hr incubation at 37°C to allow release of aberrant
bases by Aag glycosylase, oligonucleotides were chemically cleaved at
the abasic sites. Fragments were separated by 20% denaturing PAGE.
Release of Hx or «A is indicated by the appearance of either a 14-mer
or a 12-mer, respectively. (B) Liver: time-dependent release of Hx
(Upper) and «A (Lower) for liver extract proteins from Aag 1y1 mice
(136 mg) and Aag 2y2 mice (142 mg). The BSA control or extract
proteins were incubated at 37°C for the indicated times, chemically
cleaved, and analyzed as described above. (C) Testes: 100 mg of extract
proteins, prepared from the testes of two Aag 2y2 and two Aag 1y1
mice were incubated for 5 hr with Hx and «A oligonucleotide
substrates and analyzed as described above. (D) Kidney: 131 mg of
extract proteins, prepared from the kidneys of two Aag 2y2 and two
Aag 1y1 mice, were incubated for 6 hr with Hx and «A containing
oligonucleotide substrates and analyzed as described above. (E) Lung:
95 mg of extract proteins, prepared from the lungs of two Aag 2y2 and
Aag 1y1 mice, were incubated for 6 hr with Hx and «A oligonucle-
otide substrates and analyzed as described above.
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Note added in proof. Recently, viable Aag 2y2 mice that appear to be
similar to those described here have been generated independently by
another group (R. H. Elder and G. P. Margison, personal communi-
cation).
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